New research co-led by a Roswell Park Comprehensive Cancer Center leukemia expert highlights a promising investigational ...

Amphista to initiate its first clinical trial for AMX-883, a potent, orally bioavailable DCAF16-dependent degrader of BRD9, for acute myeloid ...

Surveyed oncologists reported high likelihood to prescribe (6 of 7), citing deep remissions, transplant-bridging potential, ...

As evidence continues to evolve, optimising sequencing, duration, MRD-guided use, and combination approaches will be important areas of focus to improve patient outcomes ...

Several patients with acute myeloid leukemia (AML) who were treated with SENTI-202, a chimeric antigen receptor natural killer (CAR-NK) therapy, experienced complete remission after not responding to ...

Cambridge company Amphista Therapeutics has been backed by the US FDA in its fight against a potentially deadly form of ...

What Is Revuforj, and Why Does It Matter? Revuforj (revumenib) is an oral medicine approved for treating a type of cancer called acute myeloid leukemia (AML) that affects your bone marrow and blood.

A panelist discusses how the highest unmet needs in acute myeloid leukemia include treatments for patients with refractory and relapsed disease, addressing poor outcomes in patients with TP53 ...

AvenCell Therapeutics, a clinical-stage cell therapy company developing switchable CAR-T therapies for cancer, today announced that data from the completed Phase 1a portion of the RevSTAR-123 study, ...

AbbVie (NYSE: ABBV) today announced it will share new data at the European Hematology Association (EHA) 2026 Congress and will ...